Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 7/20 | 0.67 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683473 | 0.90 | GABRA5 (0.67) | GABRA5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2688051 | 0.83 | GABRA5 (0.52) | GABRA5LPAR1PTGER4SLCO1B1 | |
| SCHEMBL2683700 | 0.83 | GABRA5 (0.69) | GABRA5LPAR1 | |
| SCHEMBL2687939 | 0.82 | GABRA5 (0.51) | GABRA5LPAR1PTGER4SLCO1B1 | |
| SCHEMBL2686909 | 0.82 | GABRA5 (0.59) | GABRA5 | |
| SCHEMBL4407568 | 0.81 | GABRA5 (1.00) | GABRA5 | |
| SCHEMBL2682578 | 0.79 | GABRA5 (0.70) | GABRA5 | |
| SCHEMBL28804946 | 0.79 | GABRA5 (0.52) | GABRA5LPAR1 | |
| SCHEMBL285797 | 0.78 | GABRA5 (0.65) | GABRA5 | |
| SCHEMBL2685549 | 0.77 | GABRA5 (0.69) | GABRA5KDM5AKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | claimed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | claimed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | claimed |
| CN-103189370-A | Triazole derivatives as ligands for GABA receptors | HOFFMANN LA ROCHE | 2013-07-03 | — | — | CN | claimed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | claimed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | claimed |
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| CN-103189370-A | Triazole derivatives as ligands for GABA receptors | HOFFMANN LA ROCHE | 2013-07-03 | — | — | CN | disclosed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885LPAR1 1367/4885HDAC3 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.